Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario
Open Access
- 1 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (suppl_2), ii59-ii65
- https://doi.org/10.1093/europace/eur080
Abstract
As in other settings, in the field of clinical use of cardiac implantable electrical devices (CIEDs), the implementation, in various ways, of diagnosis-related groups (DRGs) has created new scenarios in most European healthcare systems. A DRG system is primarily a financial tool with the aim of promoting efficiency and improving utilization of resources. However, there are a variety of ways in which this system is used for funding the activity of centres implanting CIEDs. It is possible that the specific type and method of reimbursement may influence the implementation of CIEDs in the ‘real world’ through a variable spectrum of practices. These may range from the situation where reimbursement may, together with other factors, constitute a true barrier to the implementation of guidelines, to scenarios where reimbursement is adequate, and/or to situations where reimbursement may be adequate for standard devices but not for prompt implementation of effective technological innovations. The variety in reimbursement also affects how in-office checks of CIEDs are covered and, above all, the possibility to pay for remote follow-up of CIEDs. In the field of medical devices, refinement of DRG systems and adoption of new strategies and policies are needed to sustain and enhance those effective technological innovations that may be beneficial for specific patient populations. It is also important that physicians are deeply involved in the development and deployment of DRGs, and that each country DRGs agency has a transparent approach to engagement with stakeholders, along with robust and transparent mechanisms for updating these systems.Keywords
This publication has 25 references indexed in Scilit:
- Implantable electrical devices for prevention of sudden cardiac death: data on implant rates from a 'real world' regional registryEP Europace, 2010
- The Evolution of Diagnosis-Related Groups (DRGs)Quality Management in Health Care, 2010
- Balancing adoption and affordability of medical devices in EuropeHealth Policy, 2009
- Preventing tomorrow's sudden cardiac death today: Dissemination of effective therapies for sudden cardiac death preventionAmerican Heart Journal, 2008
- ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic SurgeonsJournal of the American College of Cardiology, 2008
- The fight against sudden cardiac death: consensus guidelines as a referenceEuropean Heart Journal Supplements, 2007
- Implantable cardioverter defibrillators: from evidence of trials to clinical practiceEuropean Heart Journal Supplements, 2007
- Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm AssociationEP Europace, 2007
- The impact of reimbursement on the usage of pacemakers, implantable cardioverter defibrillators and radiofrequency ablationJournal of Interventional Cardiac Electrophysiology, 2006
- Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries.Health Care Management Science, 2006